Coronavirus Disease-2019 (COVID-19) is a recognized prothrombotic state. Patients hospitalized with active cancer are predisposed to thrombosis but whether active cancer further amplifies thrombotic risk with COVID-19 is not known.
To evaluate cumulative incidences of thrombotic and hemorrhagic events in hospitalized COVID-19 patients with and without active cancer at 28 days.
A retrospective cohort analyses of consecutive adults hospitalized with COVID-19 was performed. Active cancer required cancer-directed therapy within last 6 months. The cumulative incidences of thrombosis or hemorrhage were estimated considering death as a competing risk.
Patients without cancer (n=353) and active cancer (n=45) were comparable in terms of age, sex, antibiotics administered, length of hospitalization, and critical care. The most common malignancies were lymphoid (17.8%), gastrointestinal (15.6%), lung (13.3%), and genitourinary (13.3%). At day 28, the cumulative incidence of thrombotic events was 18.2% (95% CI, 10.2% to 27.9%) in non-cancer cohort and 14.2% (95% CI, 4.7% to 28.7%) in the cancer cohort. The cumulative incidence of major and fatal bleeding at day 28 was 20.8% (95% CI, 12.1 to 31.0%) in the non-cancer group and 19.5% (95% CI, 5.5% to 39.8%) in the cancer cohort. Three patients experienced fatal bleeds, all of whom were in the non-cancer cohort. Survival was significantly shorter in the group with active cancer (P=0.038).
We observed a similarly high incidence of thrombosis and bleeding among patients admitted with COVID-19 with or without active cancer.